Vg081821ac

Preclinical

ZZhejiang Vimgreen Pharmaceuticals, Ltd.

Vg081821ac is one of 2 therapeutic programs targeting Parkinson Disease (PD). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Parkinson Disease (PD)Recruiting

Parkinson Disease (PD)Preclinical

Recruiting

Competition

Competitive Landscape

1 competitor in Parkinson Disease (PD)

#DrugCompanyPhaseTrials

Trb-001

TTridem Bioscience FlexCo

Phase 1

1 2

Vg081821ac

ZZhejiang Vimgreen Pharmaceuticals, Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Parkinson Disease (PD)

NCT07725562

Clinical

Trials by Indication[1]

Parkinson Disease (PD)1 trial

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Clinical Trial to Evaluate the Efficacy and Safety of Oral VG081821AC Tablets Monotherapy (Without Concomitant Levodopa) in Patients With Early to Mid-Stage Parkinson's Disease

Recruiting·ZZhejiang Vimgreen Pharmaceuticals, Ltd.·Preclinical·NCT07725562·152 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Vg081821ac. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Vg081821ac. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Zhejiang Vimgreen Pharmaceuticals, Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: ZZhejiang Vimgreen Pharmaceuticals, Ltd.

Vg081821ac

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Parkinson Disease (PD)1 trial

References

Drug Info

Quick Facts

Related News